25 March 2021 
EMA/CHMP/169064/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Xtandi 
enzalutamide 
On 25 March 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Xtandi. The marketing authorisation holder for this medicinal product is Astellas Pharma Europe B.V.. 
The CHMP adopted an extension to the existing indication as follows:2  
Xtandi is indicated for: 
• 
• 
• 
• 
the treatment of adult men with metastatic hormone-sensitive prostate cancer 
(mHSPC) in combination with androgen deprivation therapy (ADT) (see section 
5.1). 
the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer 
(CRPC) (see section 5.1). 
the treatment of adult men with metastatic CRPC who are asymptomatic or mildly 
symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet 
clinically indicated (see section 5.1). 
the treatment of adult men with metastatic CRPC whose disease has progressed on or after 
docetaxel therapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
